Advanced search
Start date
Betweenand

Generation of chimeric recombinant proteins for vaccine development against Plasmodium vivax

Grant number: 11/23278-9
Support type:Scholarships in Brazil - Scientific Initiation
Effective date (Start): February 01, 2012
Effective date (End): October 31, 2013
Field of knowledge:Biological Sciences - Parasitology
Principal Investigator:Irene da Silva Soares
Grantee:Mariana Vilela Rocha
Home Institution: Faculdade de Ciências Farmacêuticas (FCF). Universidade de São Paulo (USP). São Paulo , SP, Brazil
Associated scholarship(s):13/01487-0 - Functional analyze of murine antibodies induced by immunization with a chimeric recombinant protein based on different immunodominant Plasmodium vivax antigens, BE.EP.IC

Abstract

Plasmodium vivax is the most world-widely distributed and the most prevalent specie in America. Vaccine development to P. vivax is considered a priority on the global program for the eradication of malaria. In contrast to P. falciparum, currently, there are no human vaccine trials described against infection to P. vivax. We hypothesize that an effective vaccine formulation should be composed by immunodominant regions of two or more antigens of the parasite. Based on that, our aim in this project is to generate chimeric recombinant proteins based on selected immunodominant domains of the P. vivax infective forms, merozoites. For that purpose, we selected the Apical Membrane Antigen 1 (AMA-1) and the C-terminal region of Merozoite Surface Protein 1 (MSP-1) that we previously characterized as highly immunogenic in natural infections. Chimeric proteins will be expressed in the yeast Pichia pastoris using synthetic codon optimized genes. We will evaluate the expression and establish the purification procedure. If successful, we will use these proteins for pre-clinical vaccinations in mice. The analysis of the immune response will be evaluated by serum IgG antibodies detection (ELISA) against bacterial recombinant proteins representing each one of them or the chimeric protein. This will allow us to conclude whether, in fact, the use of chimeric antigens provide advantage to enhance antibody response to immunodominant antigens

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
ROCHA, MARIANA VILELA; FRANCOSO, KATIA SANCHES; LIMA, LUCIANA CHAGAS; CAMARGO, TARSILA MENDES; MACHADO, RICARDO L. D.; COSTA, FABIO T. M.; RENIA, LAURENT; NOSTEN, FRANCOIS; RUSSELL, BRUCE; RODRIGUES, MAURICIO M.; SOARES, IRENE S. Generation, characterization and immunogenicity of a novel chimeric recombinant protein based on Plasmodium vivax AMA-1 and MSP1(19). Vaccine, v. 35, n. 18, p. 2463-2472, APR 25 2017. Web of Science Citations: 3.

Please report errors in scientific publications list by writing to: cdi@fapesp.br.